Zadina J E, Harrison L M, Ge L J, Kastin A J, Chang S L
Veteran's Administration Medical Center, New Orleans, Louisiana.
J Pharmacol Exp Ther. 1994 Sep;270(3):1086-96.
Mu and delta opiate receptor regulation by opiate agonists and antagonists was studied in the human neuroblastoma cell line SH-SY5Y. Morphine down-regulated both mu and delta receptors, but its effects on each subtype could be dissociated by use of specific antagonists. The selective mu antagonist D-Phe-Cys-Tyr-D-Trp-Arg-Pen-Thr-NH2 (CTAP) blocked the down-regulation of mu, but not delta receptors. Conversely, the delta antagonist (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH([N,N-diallyl-Tyr1, Aib2,3]Leu- enkephalin)] ICI 174,864 blocked morphine-induced down-regulation of delta but not mu receptors. These selective antagonists also were studied alone for their effects on both receptors. CTAP alone at doses of 0.1 microM and higher up-regulated mu receptors. CTAP did not affect delta receptors at 0.3 microM or less, but it down-regulated them at doses of 1 microM or more, apparently due to its delta agonist activity at higher doses, which was reversed by ICI 174,864. ICI 174,864 alone also showed complex effects on the two subtypes, up-regulating both mu and delta sites. Its effects were most selective at a low dose (0.1 microM), which upregulated delta sites with minimal effects on mu sites. The nonselective antagonist naloxone provided a more robust upregulation (> 40%) of both mu and delta receptors than either selective antagonist alone or in combination. The mu-to-delta ratio (1.4 to 1) was not altered by differentiation of the cells with retinoic acid, which up-regulated both mu and delta receptors. Differentiation with the phorbol agent 12-O-tetradecanoyl-phorbol-13-acetate, however, up-regulated mu, but not delta receptors. The selective mu agonist Tyr-Pro-MePhe-D-Pro-NH2 (PL017) down-regulated mu receptors with a half-maximal effect at 180 nM, but was without effect on delta receptors at concentrations up to 10 microM. Conversely, the selective delta agonist Tyr-D-Pen-Gly-Phe-D-Pen([D-Pen2,5]-enkephalin) (DPDPE) potently down-regulated delta receptors, producing half-maximal decreases at 0.5 nM. At doses above those that reduced the maximum binding of [3H]pCl-DPDPE binding to the delta site, DPDPE also induced an apparent loss of affinity (increased Kd) at the delta site. It was without effect on mu receptors, however, at doses up to 10 microM. Thus, down-regulation of mu and delta receptors was homologous, because selective agonists down-regulated their respective receptors without effect on the heterologous opiate receptor.(ABSTRACT TRUNCATED AT 400 WORDS)
在人神经母细胞瘤细胞系SH-SY5Y中研究了阿片类激动剂和拮抗剂对μ和δ阿片受体的调节作用。吗啡下调μ和δ受体,但使用特异性拮抗剂可区分其对每种亚型的作用。选择性μ拮抗剂D-苯丙氨酸-半胱氨酸-酪氨酸-D-色氨酸-精氨酸-青霉胺-苏氨酸-NH2(CTAP)可阻断μ受体的下调,但不影响δ受体。相反,δ拮抗剂(N,N-二烯丙基-酪氨酸-氨基异丁酸-氨基异丁酸-苯丙氨酸-亮氨酸-OH([N,N-二烯丙基-酪氨酸1,氨基异丁酸2,3]亮氨酸-脑啡肽))ICI 174,864可阻断吗啡诱导的δ受体下调,但不影响μ受体。还单独研究了这些选择性拮抗剂对两种受体的作用。剂量为0.1μM及更高的CTAP可上调μ受体。CTAP在0.3μM或更低剂量时不影响δ受体,但在1μM或更高剂量时下调δ受体,显然是由于其在较高剂量时的δ激动剂活性,而ICI 174,864可逆转这种活性。单独使用ICI 174,864对两种亚型也表现出复杂的作用,上调μ和δ位点。其作用在低剂量(0.1μM)时最具选择性,该剂量上调δ位点,对μ位点影响最小。非选择性拮抗剂纳洛酮比单独使用或联合使用的任何一种选择性拮抗剂都能更显著地上调μ和δ受体(>40%)。用视黄酸使细胞分化不会改变μ与δ的比值(1.4比1),视黄酸可上调μ和δ受体。然而,用佛波酯12-O-十四酰佛波醇-13-乙酸酯进行分化可上调μ受体,但不影响δ受体。选择性μ激动剂酪氨酸-脯氨酸-甲基苯丙氨酸-D-脯氨酸-NH2(PL017)在180 nM时以半数最大效应下调μ受体,但在浓度高达10μM时对δ受体无影响。相反,选择性δ激动剂酪氨酸-D-青霉胺-甘氨酸-苯丙氨酸-D-青霉胺([D-青霉胺2,5]-脑啡肽)(DPDPE)可有效下调δ受体,在0.5 nM时产生半数最大降低。在高于降低[3H]pCl-DPDPE与δ位点最大结合的剂量时,DPDPE还诱导δ位点亲和力明显丧失(Kd增加)。然而,在剂量高达10μM时,它对μ受体无影响。因此,μ和δ受体的下调是同源的,因为选择性激动剂下调其各自的受体,而对异源阿片受体无影响。(摘要截短至400字)